An exploratory clinical study investigating the neoadjuvant treatment of HER2-low expressing, stage II-III breast cancer with disitamab vedotin combined with penpulimab (RCVDBCIIR005).

Authors: Xiaoxiao Liu, Chunying Zhuang, Yuting Song, Ping He, Dan Zheng, Xi Yan, Xiaorong Zhong, Tinglun Tian, Bing Wei, Yu Xin Xie, Jie Chen, Qing Lv, Ting Luo

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e12620

Source: Full article

---

Abstract

e12620